Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 18 09 2018
accepted: 10 01 2019
entrez: 15 2 2019
pubmed: 15 2 2019
medline: 21 12 2019
Statut: epublish

Résumé

Influenza virus infections remain a major and recurrent public health burden. The intrinsic ever-evolving nature of this virus, the suboptimal efficacy of current influenza inactivated vaccines, as well as the emergence of resistance against a limited antiviral arsenal, highlight the critical need for novel therapeutic approaches. In this context, the aim of this study was to develop and validate an innovative strategy for drug repurposing as host-targeted inhibitors of influenza viruses and the rapid evaluation of the most promising candidates in Phase II clinical trials. We exploited

Identifiants

pubmed: 30761132
doi: 10.3389/fimmu.2019.00060
pmc: PMC6361841
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

60

Subventions

Organisme : CIHR
ID : 229733
Pays : Canada
Organisme : CIHR
ID : 230187
Pays : Canada

Références

Nat Rev Drug Discov. 2004 Aug;3(8):673-83
pubmed: 15286734
Nature. 2009 Nov 12;462(7270):175-81
pubmed: 19881490
Nat Rev Cancer. 2007 Jan;7(1):54-60
pubmed: 17186018
Curr Opin Immunol. 2013 Oct;25(5):588-92
pubmed: 24011665
Nat Rev Drug Discov. 2004 May;3(5):451-6
pubmed: 15136792
Genome Biol. 2003;4(5):P3
pubmed: 12734009
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
J Cell Biol. 1981 Jun;89(3):700-5
pubmed: 6265471
Antiviral Res. 2012 Nov;96(2):130-7
pubmed: 22909899
Antiviral Res. 2012 Dec;96(3):391-404
pubmed: 23022351
Sci Transl Med. 2011 Aug 17;3(96):96ps35
pubmed: 21849663
Biol Chem. 2011 Oct;392(10):837-47
pubmed: 21823902
Cell Microbiol. 2007 Jul;9(7):1683-94
pubmed: 17324159
Cell Host Microbe. 2018 Jun 13;23(6):809-818.e5
pubmed: 29779930
Mol Cancer Ther. 2014 Nov;13(11):2559-71
pubmed: 25189541
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Reanimation. 2016;25(Suppl 2):53-61
pubmed: 32288744
Antiviral Res. 2008 Apr;78(1):9-25
pubmed: 18313769
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Brief Bioinform. 2011 Jul;12(4):312-26
pubmed: 21441562
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
J Clin Microbiol. 2005 Aug;43(8):4139-46
pubmed: 16081961
Methods Enzymol. 2006;411:352-69
pubmed: 16939800
Nucleic Acids Res. 2014 Jan;42(Database issue):D749-55
pubmed: 24316576
J Biol Chem. 2009 Oct 23;284(43):29798-808
pubmed: 19638339
J Virol. 2003 May;77(10):5933-47
pubmed: 12719586
Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13
pubmed: 19067613
Viruses. 2015 Jul 27;7(8):4186-203
pubmed: 26225991
J Immunol. 2015 Sep 15;195(6):2580-90
pubmed: 26246143
Nat Med. 2016 Oct;22(10):1101-1107
pubmed: 27571349
Virology. 2010 Sep 1;404(2):215-24
pubmed: 20627352
PLoS One. 2010 Oct 04;5(10):
pubmed: 20957181
Cell Mol Life Sci. 2014 Oct;71(19):3659-83
pubmed: 24699705
PLoS One. 2009;4(2):e4346
pubmed: 19194489
Sci Transl Med. 2015 Jun 3;7(290):290ra89
pubmed: 26041706
J Intensive Care. 2014 Jan 03;2(1):2
pubmed: 25520820
Ann N Y Acad Sci. 1975 Aug 8;255:366-71
pubmed: 1059365
J Infect Dis. 2007 Nov 15;196(10):1493-9
pubmed: 18008229
BMC Genomics. 2010 May 31;11:344
pubmed: 20509979
Trends Pharmacol Sci. 2014 Feb;35(2):86-102
pubmed: 24439476
Antimicrob Agents Chemother. 2015 Oct;59(10):6007-16
pubmed: 26169418
Science. 2006 Sep 29;313(5795):1929-35
pubmed: 17008526
Database (Oxford). 2011 Jul 23;2011:bar030
pubmed: 21785142

Auteurs

Andrés Pizzorno (A)

Virologie et Pathologie Humaine-VirPath Team, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
Research Center in Infectious Diseases of the CHU de Quebec and Laval University, Quebec City, QC, Canada.

Olivier Terrier (O)

Virologie et Pathologie Humaine-VirPath Team, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Claire Nicolas de Lamballerie (C)

Virologie et Pathologie Humaine-VirPath Team, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
Viroscan3D SAS, Lyon, France.

Thomas Julien (T)

Virologie et Pathologie Humaine-VirPath Team, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Blandine Padey (B)

Virologie et Pathologie Humaine-VirPath Team, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Aurélien Traversier (A)

Virologie et Pathologie Humaine-VirPath Team, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Magali Roche (M)

Viroscan3D SAS, Lyon, France.

Marie-Eve Hamelin (ME)

Research Center in Infectious Diseases of the CHU de Quebec and Laval University, Quebec City, QC, Canada.

Chantal Rhéaume (C)

Research Center in Infectious Diseases of the CHU de Quebec and Laval University, Quebec City, QC, Canada.

Séverine Croze (S)

ProfileXpert, SFR-Est, CNRS UMR-S3453, INSERM US7, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Vanessa Escuret (V)

Virologie et Pathologie Humaine-VirPath Team, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
Laboratoire de Virologie, Centre National de Référence des virus Influenza Sud, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.

Julien Poissy (J)

Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille, France.

Bruno Lina (B)

Virologie et Pathologie Humaine-VirPath Team, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
Laboratoire de Virologie, Centre National de Référence des virus Influenza Sud, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.

Catherine Legras-Lachuer (C)

Viroscan3D SAS, Lyon, France.
Ecologie Microbienne, UMR CNRS 5557, USC INRA 1364, Université Claude Bernard Lyon 1, Université de Lyon, Villeurbanne, France.

Julien Textoris (J)

Service d'Anesthésie et de Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Pathophysiology of Injury-Induced Immunosuppression (PI3), EA 7426 Hospices Civils de Lyon, bioMérieux, Université Claude Bernard Lyon 1, Hôpital Edouard Herriot, Lyon, France.

Guy Boivin (G)

Research Center in Infectious Diseases of the CHU de Quebec and Laval University, Quebec City, QC, Canada.

Manuel Rosa-Calatrava (M)

Virologie et Pathologie Humaine-VirPath Team, Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH